US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Moxifloxacin Preservative Free Syr

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0040-2023
Class II · Moderate risk Ongoing

MITOMYCIN INJECTION 0.375 mg/mL SYR

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0039-2023
Class II · Moderate risk Ongoing

METHYLCOBALAMIN PF 1 ML Injection Solution 5

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0038-2023
Class II · Moderate risk Ongoing

MEDROXYPROGESTERONE ACETATE 300 MG/ML Suspension

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0037-2023
Class II · Moderate risk Ongoing

LIDOCAINE EPINEPHRINE BUFFERED 2%/1:1000 Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0036-2023
Class II · Moderate risk Ongoing

LIDOCAINE/PHENYLEPHRINE PF SYR 1%/1.5% Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0035-2023
Class II · Moderate risk Ongoing

LAURETH-9 INJ 2% Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0034-2023
Class II · Moderate risk Ongoing

GLYCERIN OPHTHALMIC DROPS 98.5% Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0033-2023
Class II · Moderate risk Ongoing

CYCLOSPORIN 0.07% OPTH 0.07% Solution in 10 mL bottles

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0032-2023
Class II · Moderate risk Ongoing

CEFUROXIME INTRAVITREAL SYR 1MG/0.1ML Solution in 1 mL syringe

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0031-2023
Class II · Moderate risk Ongoing

CEFTAZIDIME INTRAVITREAL 2.25MG/0.1ML Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0030-2023
Class II · Moderate risk Ongoing

Brilliant Blue G

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0029-2023
Class II · Moderate risk Ongoing

Autologus Tears Serum Soln Full Strength

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0028-2023
Class II · Moderate risk Ongoing

ACETYLCYSTEINE OPTH 5% Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0027-2023
Class II · Moderate risk Ongoing

ACETYLCYSTEINE OPTH 10% Solution

Reason Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0026-2023
Class II · Moderate risk Ongoing

SIREtizer Hand Sanitizer

Reason CGMP Deviations and Superpotent Drug: Levels of acetal and acetaldehyde above allowable limits. Additionally, lot 001 was superpotent.

Southwest Iowa Renewable Energy LLC D-0166-2023
Class II · Moderate risk Terminated

Rifampin Capsules

Reason Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Golden State Medical Supply Inc. NDC 51407-322-30 D-0012-2023
Class II · Moderate risk Terminated

Rifampin Capsules

Reason Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Golden State Medical Supply Inc. NDC 51407-323-30 D-0011-2023
Class II · Moderate risk Completed

Quinapril and Hydrochlorothiazide Tablets

Reason CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Aurobindo Pharma USA Inc. NDC 65862-162-90 D-0021-2023
Class II · Moderate risk Terminated

Fondaparinux Sodium Injection

Reason Subpotent Drug: Out of specification for assay

AuroMedics Pharma LLC NDC 55150-232-10 D-0020-2023
Class II · Moderate risk Terminated

Pyridostigmine Bromide Oral Solution

Reason cGMP Deviations: Out of specification for assay of one of the preservative ingredients.

VistaPharm, Inc. NDC 66689-406-01 D-0018-2023
Class II · Moderate risk Completed

Flunisolide Nasal Solution

Reason Out of specification for related substances (impurities).

Ingenus Pharmaceuticals Llc NDC 50742-317-25 D-0010-2023
Class II · Moderate risk Terminated

Aminophylline Injection

Reason Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.

Pfizer Inc. NDC 0409-5921-16 D-0003-2023
Class II · Moderate risk Completed

Acyclovir Sodium Injection

Reason Presence of Particulate Matter: Customer complaint for a dark red, brown and black particulate floating inside vial.

AuroMedics Pharma LLC NDC 55150-154-10 D-0013-2023